These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 21982237)

  • 1. Progress in endocrine approaches to the treatment and prevention of breast cancer.
    Obiorah I; Jordan VC
    Maturitas; 2011 Dec; 70(4):315-21. PubMed ID: 21982237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
    Rugo HS
    Ann Oncol; 2008 Jan; 19(1):16-27. PubMed ID: 17693420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A; Howell SJ; Clarke R; Anderson E
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention.
    Tobias JS
    Ann Oncol; 2004 Dec; 15(12):1738-47. PubMed ID: 15550578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.
    Vogel VG
    Curr Drug Targets; 2011 Dec; 12(13):1874-87. PubMed ID: 21158712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.
    Dunn BK; Ryan A
    Ann N Y Acad Sci; 2009 Feb; 1155():141-61. PubMed ID: 19250201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
    de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
    Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.
    Carlson RW; Hudis CA; Pritchard KI; ; ;
    J Natl Compr Canc Netw; 2006 Nov; 4(10):971-9. PubMed ID: 17112447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics of endocrine therapy in breast cancer.
    Ingle JN
    J Hum Genet; 2013 Jun; 58(6):306-12. PubMed ID: 23635953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors.
    Fentiman IS
    Int J Clin Pract; 2006 Jun; 60(6):689-93. PubMed ID: 16805754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The endocrine prevention of breast cancer.
    Howell A
    Best Pract Res Clin Endocrinol Metab; 2008 Aug; 22(4):615-23. PubMed ID: 18971122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Carlson RW; Henderson IC
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selecting adjuvant endocrine therapy for breast cancer.
    Eneman JD; Wood ME; Muss HB
    Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of hormone-related cancers: breast cancer.
    Dunn BK; Wickerham DL; Ford LG
    J Clin Oncol; 2005 Jan; 23(2):357-67. PubMed ID: 15637398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exemestane for primary prevention of breast cancer in postmenopausal women.
    Zhang Y; Simondsen K; Kolesar JM
    Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT; Robert NJ
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.